For how we live.
An FDA advisory committee will meet on 30 October to review Sydnexis's atropine sulfate 0.01% eye drops, proposed to slow myopia progression in children aged 3 and older. The public docket closes 29 October.
The Essilor-designed HAL lenses cut two-year myopia progression by 71% versus ordinary glasses in 159 American children. The company employs the study's authors, and the result backs the device's US clearance.
Reading in poor light makes eyes feel tired, but there is no evidence it causes lasting damage. What really shapes eyesight is near-work load and time in bright daylight — and it acts in childhood.
Eye strain is close to universal among heavy device users, and it is temporary. The evidence that screen time causes myopia is real but weak, and every study of it measured screen time by questionnaire.
Cochrane's living review of 104 trials rates high-dose atropine and orthokeratology moderate certainty. The low-dose atropine most widely used sits at very low certainty, and two Western trials disagree.
A cluster-randomised trial in Guangzhou cut three-year myopia incidence by 9.1 percentage points with 40 extra minutes outdoors a day. The eye's underlying growth barely changed.